



Citation: 2021 BCSECCOM 197

Cease Trade Order

**Michael Malana
Mariusz Olejniczak
(each referred to separately as the Insider)**

And

WPD Pharmaceuticals Inc.

Section 164 of the *Securities Act*, R.S.B.C. 1996, c. 418

- ¶ 1 WPD Pharmaceuticals Inc. is a reporting issuer and has not filed:
1. annual audited financial statements for the year ended December 31, 2020, as required under Part 4 of National Instrument 51-102 *Continuous Disclosure Obligations* (NI 51-102), and
 2. a Form 51-102F1 *Management's Discussion and Analysis* for the period ended December 31, 2020, as required under Part 5 of NI 51-102
- (the required records).
- ¶ 2 The Insider may have knowledge of, or access to, a material fact or material change regarding WPD Pharmaceuticals that has not been generally disclosed.
- ¶ 3 WPD Pharmaceuticals has agreed to file, immediately after this order is granted, the Notice of Default and, if applicable, Default Status Reports, set out in National Policy 12-203 *Management Cease Trade Orders*.
- ¶ 4 Under section 164(1) of the Act, the Executive Director orders that all trading by the Insider in the securities of WPD Pharmaceuticals cease until:
1. WPD Pharmaceuticals files the required records, completed in accordance with the Act and rules, and
 2. the Executive Director revokes this order.
- ¶ 5 May 4, 2021

Anita Cyr, CPA, CA
Manager, Financial Reporting
Corporate Finance